e-learning
resources
Vienna 2003
Tuesday 30.09.2003
From biopsy to treatment of diffuse lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Expression of apoptotic markers in patients with idiopathic pulmonary fibrosis
M. Plataki, A. Koutsopoulos, K. Darivianaki, G. Delides, N. M. Siafakas, D. Bouros (Heraklion, Alexandroupolis, Greece)
Source:
Annual Congress 2003 - From biopsy to treatment of diffuse lung diseases
Session:
From biopsy to treatment of diffuse lung diseases
Session type:
Oral Presentation
Number:
2436
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Plataki, A. Koutsopoulos, K. Darivianaki, G. Delides, N. M. Siafakas, D. Bouros (Heraklion, Alexandroupolis, Greece). Expression of apoptotic markers in patients with idiopathic pulmonary fibrosis. Eur Respir J 2003; 22: Suppl. 45, 2436
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Expression of mRNA of selected inflammatory markers in BALf cells from patients with sarcoidosis and idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Apoptosis in epithelial cells in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2004; 24: Suppl. 48, 481s
Year: 2004
Decreased BCL-2 expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
PD-L1 expression in patients with idiopathic pulmonary fibrosis.
Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia
Year: 2021
IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 373s
Year: 2007
Distinct gene expression profiles of cultured stromal cells from the patients with idiopathic pulmonary fibrosis and lung adenocarcinoma
Source: International Congress 2015 – Translational studies in airway cell biology
Year: 2015
The markers of inflammatory process activity and fybrogenesis activity in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease I
Year: 2012
Upregulation of Fas-signalling molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2001; 17: 180-189
Year: 2001
Tryptase+ mast cells associate with fibrotic regions in the lungs of idiopathic pulmonary fibrosis patients; a multiplex staining approach
Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease
Year: 2016
Polymorphism of the genes of xenobiothics detoxification in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2004; 24: Suppl. 48, 536s
Year: 2004
Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis
Source: Eur Respir J 2007; 30: Suppl. 51, 574s
Year: 2007
Aquoaporin-1 expression in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Neutrophil-rich inflammation in induced sputum of patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2001; 18: Suppl. 33, 409s
Year: 2001
Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Airway remodelling: recent developments
Year: 2015
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
NHLRC2 mRNA and protein expression in idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia
Year: 2021
Altered expression of adhesion molecules in circulating neutrophils of patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2002; 20: Suppl. 38, 479s
Year: 2002
Autoantibodies in patients with idiopathic pulmonary fibrosis
Source: International Congress 2019 – Interstitial lung disease registries
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept